Description: Teneglee 20 Tablets contain teneligliptin which is a dipeptidyl peptidase-4 (DPP-4) inhibitor. Pharmaceutical Dosage Form: Tablet Route of Administration: Oral Composition:
| Each film coated tablet contains: | ||
| Teneligliptin hydrobromide hydrate Eq. to Teneligliptin | IP | 20 mg |
| Excipients | q.s. | |
Mechanism of Action: The glucagon-like peptide-1 (GLP-1) is secreted from alimentary canal in response to meal that promotes insulin secretion from pancreas and regulates blood sugar post meal by controlling glucagon secretion. Teneligliptin exhibits a hypoglycemic effect by controlling the decomposition of GLP-1 by inhibiting dipeptidyl peptidase-4 (DPP-4) activity and thereby increasing blood concentration of active GLP-1. Indications: Teneglee 20 Tablets are indicated for the treatment of type 2 Diabetes Mellitus as a monotherapy adjunct to diet and exercise. Dosage: As directed by the physician. Storage: Store in a dry place protected at a temperature not exceeding 30°C. Protect from light. Presentation: 10 X 15 Tablets Side effects: Hypoglycemia, Dizziness, Headache, Constipation, Diarrhoea, Abdominal pain, Hepatic steatosis, Rashes, Edema. Contraindications: Teneglee 20 Tablets are contraindicated in patients with severe ketosis, diabetic coma or pre-coma, type 1 diabetes, severe trauma, renal failure or acute or chronic disease which may cause tissue hypoxia such as: cardiac or respiratory failure, recent myocardial infarction, shock, hepatic insufficiency, acute alcohol intoxication and alcoholism (due to the metformin component). Drug Interactions: Teneglee 20 Tablets can cause drug interaction with following drugs: Other antidiabetics Furosemide Ketoconazole combination Class IA anti arrhythmic drugs: Quinidine Sulfate Hydrate, Procainamide Hydrochloride Cholestyramine Class III antiarrhythmic drugs: Amiodarone Hydrochloride, Sotalol Hydrochloride β-blocking agents Salicylic acid drugs Monoamine oxidase inhibitor Adrenaline Adrenocortical hormone Thyroid hormone